Denise Myshko

The switch to biosimilars helped Navitus clients offset increased utilization in the non-specialty category and the introduction of higher-cost specialty drugs.

The FDA is asking for information about the manufacturing process, as well as the type 1 diabetes indication.

The FTC’s interim report on pharmacy benefit managers (PBMs) was just the latest effort to highlight what some say is an industry that profits at the expense of patients and independent pharmacists. The PBMs say the report paints an incomplete, misleading picture. Others say it shows the FTC is prepping its antitrust case.

The PBM industry said the FTC has not been objective, and that efforts to limit PBM negotiating tools would put patients at the mercy of drug manufacturers.

Findings from observational studies in the past have not been consistent on the link between type 1 diabetes and epilepsy.

Company officials have said the bundled payment program could negatively impact sales of Xphozah, which was approved last year to reduce serum phosphorus in patients with kidney disease on dialysis.

Donanemab — now with the brand name of Kisunla — slows cognitive and functional decline by up to 35% and has a list price of $695.65 per vial.

A new guidance aims to provide a consensus on autoantibody testing and monitoring to identify those with early-stage type 1 diabetes whose disease could progress.

The 3Axis Advisors analysis suggests PBMs’ spread pricing practices leads to employers being charged different amounts for the same medications and to pharmacists facing reimbursement challenges.

The newspaper’s investigation, which included interviewing 300 peole, found that pharmacy benefit manager often act in their own financial interest by overcharging employers and government programs.

Nathan Downhour, Pharm.D., discusses the Pharmacy Match program, which will engage with physicians to make sure a specialty prescription gets to the best-fit pharmacy across a network powered by Free Market Health.

Full approval was granted for the one-time gene therapy to ambulatory patients aged 4 years older. The FDA also granted accelerated approval to Elevidys for non-ambulatory patients.

Global mortality fell 13 times faster in countries with a high sociodemographic index compared with countries with a low-middle sociodemographic index.

Physicians in a new survey by the American Medical Association said prior authorization leads to delayed care and a high administration burden for physician practices.

A study in mice, researchers at the University of Michigan have found infection with RSV can alter lung function in young children.

CNN political commentators Scott Jennings and Van Jones briefly touched on the upcoming election’s impact on healthcare at the annual AHIP meeting in Las Vegas.

Hackers are learning health plans’ infrastructure and are attacking the places with the highest value information. Transferring data is the weakest point in the healthcare ecosystem, panelists said at the AHIP meeting in Las Vegas.

Increased health demand, decreased physician workforce, technology advancements and more government involvement in healthcare present challenges — and opportunities — for health plans, said session panelists at the annual AHIP meeting in Las Vegas.

Working with providers to align goals and objectives will lead to better and more successful programs to help manage complex and costly medical conditions, said panelists at the annual AHIP meeting in Las Vegas.

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about how GLP-1 agonist drugs like Wegovy and Zepbound are changing the paradigm for weight loss.

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about the issues insurers consider when providing coverage for GLP-1 drugs like Wegovy and Zepbound that can help patients lose weight.

Geeta Nayyar, M.D., a rheumatologist and author, discusses how misinformation and disinformation is eroding the trust between doctors and patients, and how healthcare organizations can be part of the solution.

Committee members, however, also said more data are needed on donanemab to treat patients in underrepresented patient groups, including Latin American and African American patients and special populations such as Down syndrome.

Included in this review will be 11 drugs that ICER assessed for cost-effectiveness in 2022. New this year is an assessment for consumer accessibility of drugs, including the burdens of prior authorization and patient cost-sharing measures.

Eating disorders among patients with type 1 diabetes have increased, which increases the risk for serious complications. Patients who skip insulin doses are at a three times greater risk of premature death.

Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.

A simulation model projects there could savings if patients are switched to lower cost drugs or programs after initial weight loss using GLP-1 drugs.

In a study in mice, researchers found that the COVID-19 virus can infect the retina even when the virus doesn’t enter through the eyes.

The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantle cell lymphoma. The agency has delay a decision on Dupixent in COPD and has set goal dates for zolbetuximab in gastric cancer and zanidatamab in bile duct cancer.

LucyRx will begin providing pharmacy benefit services to self-insured employers, covering about half a million lives, beginning in January 2025.